AssayIndex

FGP-2604-K9878

MK-677 (Ibutamoren mesylate) · 500 mg declared · Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. · manufactured 01 Apr 2026

CHARACTERISED
Lot code
FGP-2604-K9878
Supplier
FGP — Flourishglobal Peptide Biotech (Chengdu) Co., Ltd.
Compound
MK-677 (Ibutamoren mesylate)
Compound class
Non-peptide adjuncts
Declared label claim
500mg
Manufacture date
01 Apr 2026
Index quarter
2026-Q2
Independent assays
7
Laboratories involved
PeptideMeter, Janoshik, Nordanalyt, Medutest
Provenance mix
Buyer-sourced ×7
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 7
Median purity 99.82% n=7
Spread (max − min) 0.38pp n=7
Standard deviation 0.151pp n=7
97.597.998.498.899.299.7100.1This lot (FGP-2604-K9878)This lot (FGP-2604-K9878): Q1 99.71, median 99.82, Q3 99.91, n=7n=7All MK-677 (Ibutamoren mesylate)All MK-677 (Ibutamoren mesylate): Q1 98.84, median 99.42, Q3 99.75, n=139n=139 Purity (% area)
Figure 1. This lot's independent purity results against the whole MK-677 (Ibutamoren mesylate) record set in the index. The vertical line is the index acceptance specification for the non-peptide adjuncts class, 98.5 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 7

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041750FGP-2604-K9878PeptideMeter2026-Q299.825.03Buyer-sourced0FAIL
AX-2026-041751FGP-2604-K9878Janoshik2026-Q299.795.6988.7Buyer-sourced1FAIL
AX-2026-041752FGP-2604-K9878Nordanalyt2026-Q299.935.39100.9Buyer-sourced0FAIL
AX-2026-041753FGP-2604-K9878Janoshik2026-Q299.935.7288.7Buyer-sourced1FAIL
AX-2026-041754FGP-2604-K9878Janoshik2026-Q299.895.0693.8Buyer-sourced0FAIL
AX-2026-041755FGP-2604-K9878Medutest2026-Q299.554.81105.7Buyer-sourced0FAIL
AX-2026-041756FGP-2604-K9878Janoshik2026-Q299.624.4189.4Buyer-sourced1FAIL
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
PeptideMeter199.8299.8228min-0.0599.87
Janoshik499.79, 99.93, 99.89, 99.6299.8430min+0.0099.84
Nordanalyt199.9399.9335min+0.0299.91
Medutest199.5599.5525min+0.0899.47

This lot contributes 6 paired comparisons to the inter-lab analysis.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)99.8099.82divergence -0.02 pp vs batch median
Total impurities (% area)0.200.18
Largest single impurity (% area)not stated0.12
Water (%)not stated5.03
Counter-ion (%)7.515.71
Peptide content (%w/w)88.4not determined
Endotoxin (EU/mg)not stated1.03
Method stated on certificateNOno method section — the result cannot be reconciled against any other
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
spiroindane regioisomer7 / 70.040.02–0.24
free base (des-mesylate, −96 Da)4 / 70.100.04–0.18
sulfonamide hydrolysis product (+18 Da)4 / 70.030.02–0.05
residual DMF (process solvent)4 / 70.040.03–0.09
O-desmethyl metabolite analogue (−14 Da)2 / 70.050.03–0.07
Section 7

What this rollup does not establish